	ARTICLE	ARTICLE DATE	SENTENCE NUM	SENTENCE	IGNORANCE CATEGORIES	NUM IGNORANCE CATEGORIES	OBO ID (LABEL)
S32-PMC5901203	PMC5901203	4/2018	S32-PMC5901203	['Opioid prescriptions in the first Trimester increased by 33.9% from 1995 to 2009 for non-cancer pain diagnoses INDICATING that pain syndromes during Pregnancy are being increasingly treated with prescription Opioids.14THIS FINDING is NOT SURPRISING AS Opioids are OFTEN second-line treatment options during Pregnancy, after Acetaminophen, DUE to the established efficacy in acute conditions and LIMITED Reproductive safety data of OTHER Pharmacological options.15coinciding with the increase in prescription Opioid use is an increasing rise in rates of infant with neonatal abstinence syndrome (nas), a syndrome RELATED to Opioid exposure in utero that is characterized by DIFFICULTIES with Feeding and sleeping as well as Central Nervous System dysfunction.16a single source, the canadian guideline for the use of Opioids in the treatment of chronic noncancer pain, has published treatment guidelines that RECOMMEND the following: 1) Opioids SHOULD BE tapered and discontinued or prescribed at the lowest effective dose; 2) in the Postpartum Period, Codeine use SHOULD BE avoided or LIMITED to 4 days; 3) women SHOULD BE managed by Perinatologists; and 4) women with Opioid use disorders SHOULD BE referred for appropriate treatment.17the formulation of these GUIDELINES is INFLUENCED by the POTENTIAL addictive and Teratogenic EFFECTS of Opioids (ie, Cardiovascular Birth defects, Neural Tube defects, hydrocephaly, glaucoma, nas, gastroschisis, and fetal death)18–21as well as the CORRELATION of codeine with planned cesarean Delivery, Postpartum hemorrhage,22and infant death in a breastfeeding mother who is a Cyp2D6 ultra-rapid metabolizer.23no Opioid is given preference in these guidelines OWING TO LACK OF DATA supporting individual medications.']	[('INCOMPLETE_EVIDENCE', 111), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 216), ('INCOMPLETE_EVIDENCE', 223), ('PROBABLE_UNDERSTANDING', 234), ('PROBABLE_UNDERSTANDING', 249), ('PROBABLE_UNDERSTANDING', 264), ('IMPORTANT_CONSIDERATION', 339), ('INCOMPLETE_EVIDENCE', 395), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 431), ('SUPERFICIAL_RELATIONSHIP', 612), ('DIFFICULT_TASK', 673), ('FUTURE_WORK', 907), ('FUTURE_WORK', 943), ('FUTURE_WORK', 1063), ('INCOMPLETE_EVIDENCE', 1084), ('FUTURE_WORK', 1112), ('FUTURE_WORK', 1189), ('PROBABLE_UNDERSTANDING', 1261), ('SUPERFICIAL_RELATIONSHIP', 1275), ('INCOMPLETE_EVIDENCE', 1293), ('SUPERFICIAL_RELATIONSHIP', 1329), ('SUPERFICIAL_RELATIONSHIP', 1484), ('PROBABLE_UNDERSTANDING', 1698), ('PROBLEM_COMPLICATION', 1698), ('INCOMPLETE_EVIDENCE', 1707), ('ANOMALY_CURIOUS_FINDING', 1712)]	26	[('CHEBI_33903', 'glucuronates', 0, 'Opioid'), ('GO_0009294', 'DNA mediated transformation', 34, 'trimester'), ('GO_0007565', 'female pregnancy', 149, 'pregnancy'), ('CHEBI_35998', 'tridecane', 208, 'opioids'), ('CHEBI_35998', 'tridecane', 252, 'opioids'), ('GO_0007565', 'female pregnancy', 307, 'pregnancy'), ('CHEBI_15343', 'acetaldehyde', 324, 'acetaminophen'), ('GO_0000003', 'reproduction', 403, 'reproductive'), ('CHEBI_52217', 'pharmaceutical', 437, 'pharmacological'), ('CHEBI_35701', 'ester', 508, 'opioid'), ('CHEBI_35701', 'ester', 623, 'opioid'), ('GO_0007631', 'feeding behavior', 691, 'feeding'), ('UBERON_0001017', 'central nervous system', 723, 'central nervous system'), ('CHEBI_33101', 'nitrogen dioxide', 815, 'Opioids'), ('CHEBI_35998', 'tridecane', 935, 'opioids'), ('GO_0007565', 'female pregnancy', 1032, 'postpartum'), ('UBERON_2001055', 'pronephric duct opening', 1043, 'period'), ('CHEBI_16714', 'codeine', 1051, 'codeine'), ('GO_0043277', 'apoptotic cell clearance', 1133, 'perinatologists'), ('UBERON_0022283', 'pineal recess of third ventricle', 1133, 'perinatologists'), ('CHEBI_35701', 'ester', 1168, 'opioid'), ('CHEBI_50905', 'teratogenic agent', 1317, 'teratogenic'), ('CHEBI_35998', 'tridecane', 1340, 'opioids'), ('UBERON_0004535', 'cardiovascular system', 1353, 'cardiovascular'), ('GO_0007567', 'parturition', 1368, 'birth'), ('UBERON_0001049', 'neural tube', 1383, 'neural tube'), ('GO_0007567', 'parturition', 1529, 'delivery'), ('GO_0007565', 'female pregnancy', 1539, 'postpartum'), ('PR_000006099', 'cytochrome P450 17A1', 1615, 'CYP2D6'), ('CHEBI_35701', 'ester', 1651, 'opioid')]
S80-PMC4995778	PMC4995778	8/2016	S80-PMC4995778	['caption (table-wrap): table 4\n\nmajor and minor Birth defects with POSSIBLE temporal RELATIONSHIPATO exposuremajor Birth defectsminor Birth defectsgestational age at last natalizumab dosematernal concomitant medicationsabsent right femurna4\xa0weeksazelastine Nasal, Prenatal Vitamins, zolpidemanomaly of Nose, cystic dysplasia of Kidney, holoprosencephalysandal Toe gap, small anterior Fontanelle3\xa0weeksmethylphenidate, Prenatal vitaminsatrial shuntna1\xa0weekheparin Sodium, Prenatal Vitaminschordee with hypospadiasna26\xa0daysfluvoxamine, Hydrocodone/Acetaminophen, lamotrigine, Meperidine/promethazine, Ondansetron Hydrochloride, Prenatal Vitaminscolpocephaly, hydrocephalus, partial agenesis of Corpus Callosumna4\xa0daysmethylprednisolone Sodium Succinate, sertraline Hydrochloridehydronephrosisna5\xa0weekslevothyroxine, Metformin, sertraline Hydrochloridepenile concealmentna3\xa0weeksprenatal Vitaminspolydactylyna5\xa0daysfolic Acid, insulintetralogy of fallotna0 (29\xa0days prior to lmp)Duloxetine, Prenatal Vitamins, Topiramate, Trazodonetorticollisna8\xa0weeksbupropion, Methylprednisolone, Pantoprazole, Propoxyphene/ Acetaminophen, Topiramatetricuspid Valve atresiana3\xa0weeksnrventricular Septal defectna1\xa0daynrnacongenital hypothyroidism4.5\xa0weeksnitrofurantoin, Prenatal Vitamins, rh0(d) immune globulin, venlafaxine Hydrochloridenairregular Tragus, Umbilical hernia11\xa0weeksprenatal vitaminsnamongolian spot3\xa0weeksescitalopram, Hydrocodone, Levothyroxine, Modafinil, Prenatal vitaminsnasacral dimple, Umbilical hernia5\xa0weeksprenatal Vitamins, valacyclovirnasubcutaneous Cyst3\xa0weeksprenatal Vitaminsnatight frenulum3\xa0daysprenatal Vitamins, Tizanidine\nabbreviations : Lmp last Menstrual Period, na not applicable, nr not reported\napotential RELEVANCE of the timing of Natalizumab exposure to the Birth defect(s) was evaluated and coded by the Geneticist as “known cause”, “unknown cause”, “no association”, or “POSSIBLE ASSOCIATION”\n\nspontaneous Abortions and fetal demise\namong the 355 Pregnancies resulting in 363 known Pregnancy outcomes, mean Gestational age at enrollment was 11.8\xa0weeks (sd, 6.8\xa0weeks; range 3–39 weeks).']	[('INCOMPLETE_EVIDENCE', 66), ('SUPERFICIAL_RELATIONSHIP', 84), ('IMPORTANT_CONSIDERATION', 1728), ('INCOMPLETE_EVIDENCE', 1898), ('SUPERFICIAL_RELATIONSHIP', 1907)]	5	[('GO_0007567', 'parturition', 47, 'birth'), ('GO_0007567', 'parturition', 114, 'birth'), ('GO_0007567', 'parturition', 133, 'birth'), ('UBERON_0000004', 'nose', 256, 'nasal'), ('GO_0007565', 'female pregnancy', 263, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 272, 'vitamins'), ('UBERON_0000004', 'nose', 301, 'nose'), ('UBERON_0002113', 'kidney', 327, 'kidney'), ('UBERON_0001466', 'pedal digit', 359, 'toe'), ('UBERON_0002389', 'manual digit', 383, 'fontanelle3'), ('GO_0007565', 'female pregnancy', 417, 'prenatal'), ('CHEBI_52632', 'potassium-39 atom', 462, 'sodium'), ('GO_0007565', 'female pregnancy', 470, 'prenatal'), ('CHEBI_50886', 'tin disulfide', 479, 'vitaminsChordee'), ('CHEBI_5779', 'hydrocodone', 533, 'hydrocodone'), ('CHEBI_15343', 'acetaldehyde', 545, 'acetaminophen'), ('CHEBI_6757', 'mephenytoin', 573, 'meperidine'), ('CHEBI_50313', 'onium cation', 598, 'ondansetron'), ('CHEBI_17883', 'hydrogen chloride', 610, 'hydrochloride'), ('GO_0007565', 'female pregnancy', 625, 'prenatal'), ('CHEBI_83530', 'atenolol-desisopropyl', 634, 'vitaminsColpocephaly'), ('UBERON_0034924', 'aligned anatomical group', 691, 'corpus callosumNA4'), ('CHEBI_32139', 'sodium hydrogencarbonate', 733, 'sodium succinate'), ('CHEBI_67397', 'chermesinone B', 762, 'hydrochlorideHydronephrosisNA5'), ('CHEBI_6801', 'metformin', 813, 'metformin'), ('CHEBI_51318', '2-vinylaziridine', 835, 'hydrochloridePenile'), ('CHEBI_83416', '1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5-trisphosphate)(7-)', 884, 'vitaminsPolydactylyNA5'), ('CHEBI_37527', 'acid', 917, 'acid'), ('CHEBI_4723', 'Dunnione', 975, 'Duloxetine'), ('GO_0007565', 'female pregnancy', 987, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 996, 'vitamins'), ('CHEBI_63631', 'topiramate', 1006, 'topiramate'), ('CHEBI_64157', 'imetit(2+)', 1018, 'trazodoneTorticollisNA8'), ('CHEBI_52498', 'zineb', 1058, 'methylprednisolone'), ('CHEBI_7915', 'pantoprazole', 1078, 'pantoprazole'), ('CHEBI_15362', 'hydroxyacetone phosphate', 1092, 'propoxyphene'), ('CHEBI_15343', 'acetaldehyde', 1106, 'acetaminophen'), ('CHEBI_83627', 'hexadecanoyl-AMP(1-)', 1121, 'topiramateTricuspid'), ('UBERON_0003978', 'valve', 1141, 'valve'), ('UBERON_0003037', 'septum', 1177, 'septal'), ('GO_0007565', 'female pregnancy', 1251, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 1260, 'vitamins'), ('CHEBI_65298', 'phosphatidylcholine 30:5', 1306, 'hydrochlorideNAIrregular'), ('UBERON_0010887', 'tragus', 1331, 'tragus'), ('UBERON_0007118', 'umbilicus', 1339, 'umbilical'), ('CHEBI_5779', 'hydrocodone', 1417, 'hydrocodone'), ('CHEBI_6437', 'levetiracetam', 1430, 'levothyroxine'), ('CHEBI_31859', 'modafinil', 1445, 'modafinil'), ('GO_0007565', 'female pregnancy', 1456, 'prenatal'), ('UBERON_0007118', 'umbilicus', 1490, 'umbilical'), ('CHEBI_33277', 'gamma-tocotrienol', 1522, 'vitamins'), ('UBERON_0003123', 'pharyngeal arch artery 6', 1559, 'cyst3'), ('CHEBI_85646', 'avilamycin A', 1579, 'vitaminsNATight'), ('CHEBI_33277', 'gamma-tocotrienol', 1618, 'vitamins'), ('CHEBI_63629', 'tizanidine', 1628, 'tizanidine'), ('UBERON_0014287', 'medial accessory olive', 1655, 'LMP'), ('GO_0007613', 'memory', 1664, 'menstrual'), ('UBERON_0006505', 'palmar interosseous muscle of manus', 1664, 'menstrual period'), ('CHEBI_66611', 'nardoperoxide', 1755, 'natalizumab'), ('GO_0007567', 'parturition', 1783, 'birth'), ('SO_0000704', 'gene', 1830, 'geneticist'), ('GO_0006915', 'apoptotic process', 1933, 'abortions'), ('GO_0007565', 'female pregnancy', 1974, 'pregnancies'), ('GO_0007565', 'female pregnancy', 2009, 'pregnancy'), ('GO_0007565', 'female pregnancy', 2034, 'gestational')]
S46-PMC5901203	PMC5901203	4/2018	S46-PMC5901203	['in a large prospective, observational study, Triptan (ie, sumatriptan, rizatriptan, zolmitriptan, eletriptan, naratriptan, Almotriptan) use in the 6 months prior to Pregnancy was ASSOCIATED with an INCREASED RISK of stillbirth.62the same STUDY FOUND that Triptan use during Pregnancy was not associated with an increased rate of major congenital malformations, while use in the second and third trimester was ASSOCIATED with an increased risk of atonic Uterus and Blood loss >500 ml during Labor.62maternal prescription of a Sumatriptan during Pregnancy was not associated with increased Teratogenic risk63but was ASSOCIATED with an increased risk of Preterm Delivery.64an examination of children with in utero exposure to Triptans (ie, sumatriptan, rizatriptan, zolmitriptan, eletriptan, naratriptan, almotriptan, frovatriptan) at 3 years of age SHOWED a positive ASSOCIATION with externalizing behaviors BUT no association with altered or delayed Psychomotor function, communication, or temperament development.51,65metoclopramide with or without Acetaminophen CAN also be used to treat both acute migraines as well as accompanying nausea without adverse Perinatal effects.66EVIDENCE SUPPORTING the use of OTHER Antiemetics for acute treatment of migraine was NOT FOUND.']	[('SUPERFICIAL_RELATIONSHIP', 179), ('IMPORTANT_CONSIDERATION', 198), ('INCOMPLETE_EVIDENCE', 238), ('INCOMPLETE_EVIDENCE', 244), ('SUPERFICIAL_RELATIONSHIP', 409), ('SUPERFICIAL_RELATIONSHIP', 614), ('INCOMPLETE_EVIDENCE', 847), ('SUPERFICIAL_RELATIONSHIP', 865), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 906), ('ANOMALY_CURIOUS_FINDING', 906), ('INCOMPLETE_EVIDENCE', 1063), ('INCOMPLETE_EVIDENCE', 1175), ('INCOMPLETE_EVIDENCE', 1186), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1208), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1262)]	15	[('CHEBI_27026', 'toxin', 45, 'triptan'), ('CHEBI_520985', 'almotriptan', 123, 'almotriptan'), ('GO_0007565', 'female pregnancy', 165, 'pregnancy'), ('CHEBI_27026', 'toxin', 255, 'triptan'), ('GO_0007565', 'female pregnancy', 274, 'pregnancy'), ('UBERON_0000995', 'uterus', 453, 'uterus'), ('UBERON_0000178', 'blood', 464, 'blood'), ('GO_0007612', 'learning', 490, 'labor'), ('CHEBI_45373', 'sulfanilamide', 525, 'sumatriptan'), ('GO_0007565', 'female pregnancy', 544, 'pregnancy'), ('CHEBI_50905', 'teratogenic agent', 588, 'teratogenic'), ('GO_0031649', 'heat generation', 588, 'teratogenic'), ('GO_0007565', 'female pregnancy', 651, 'preterm'), ('GO_0007567', 'parturition', 659, 'delivery'), ('CHEBI_26376', '4-{[(2-amino-4-hydroxypteridin-6-yl)methyl]amino}benzoate', 723, 'triptans'), ('GO_0036343', 'psychomotor behavior', 949, 'psychomotor'), ('CHEBI_15343', 'acetaldehyde', 1049, 'acetaminophen'), ('GO_0036268', 'swimming', 1157, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 1157, 'perinatal'), ('CHEBI_35492', 'cystine zwitterion', 1214, 'antiemetics')]
S55-PMC4910734	PMC4910734	6/2015	S55-PMC4910734	['NOT ONLY is the Acetaldehyde intermediate responsible for the NOTORIOUS asian flush reaction and OTHER unpleasant EFFECTS, which discourage Ethanol ingestion, BUT the Aldh2 mutation HAS also been ASSOCIATED with an increased risk of Gastrointestinal, Esophageal, Colon, and Liver cancers20as well as late-onset alzheimer’s disease,21even in the absence of long-term Ethanol usage.']	[('ANOMALY_CURIOUS_FINDING', 0), ('IMPORTANT_CONSIDERATION', 62), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 97), ('SUPERFICIAL_RELATIONSHIP', 114), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 159), ('IMPORTANT_CONSIDERATION', 182), ('SUPERFICIAL_RELATIONSHIP', 196)]	7	[('CHEBI_15343', 'acetaldehyde', 16, 'acetaldehyde'), ('CHEBI_16236', 'ethanol', 140, 'ethanol'), ('PR_000003923', 'aldehyde dehydrogenase X, mitochondrial', 167, 'ALDH2'), ('UBERON_0005409', 'alimentary part of gastrointestinal system', 233, 'gastrointestinal'), ('UBERON_0011358', 'infundibular organ', 251, 'esophageal'), ('UBERON_0001155', 'colon', 263, 'colon'), ('UBERON_0002107', 'liver', 274, 'liver'), ('CHEBI_16236', 'ethanol', 366, 'ethanol')]
S244-PMC5215441	PMC5215441	7/2016	S244-PMC5215441	['an ALTERNATIVE mechanism by which Colonic bacteria can establish a biological response in the host is by the variety of fermentation products produced by the microbiota including short‐chain Fatty Acids (scfas), Ethanol, trimethylamine, Acetaldehyde, and Inflammatory Mediators55.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 3)]	1	[('UBERON_0001155', 'colon', 34, 'colonic'), ('CHEBI_35366', 'fatty acid', 191, 'fatty acids'), ('CHEBI_16236', 'ethanol', 212, 'ethanol'), ('CHEBI_15343', 'acetaldehyde', 237, 'acetaldehyde'), ('CHEBI_66898', '(3R)-11-cis-3-hydroxyretinal', 255, 'inflammatory mediators55')]
S50-PMC4910734	PMC4910734	6/2015	S50-PMC4910734	['the seven Human adh Genes, listed intable 1, are closely clustered on chromosome 4 (4q21-4q25), in the following 5′ to 3′ order: adh7 , Adh1C , Adh1B , Adh1A , adh6 , adh4 , and adh5 .17,18to date, hundreds of mutations in the coding and Noncoding regions of the adh Genes HAVE BEEN IDENTIFIED, which are ASSOCIATED with either alcoholism or an aversion to alcoholism.19for example, the Adh1B*2 Allele, found in high frequency in asians and a lower frequency in european, african, and jewish populations, APPEARS TO have a PROTECTIVE EFFECT against Alcohol dependence because the mutation increases the rapid oxidation of Ethanol, thus forming the toxic Acetaldehyde intermediate.']	[('INCOMPLETE_EVIDENCE', 273), ('INCOMPLETE_EVIDENCE', 283), ('SUPERFICIAL_RELATIONSHIP', 305), ('ANOMALY_CURIOUS_FINDING', 505), ('SUPERFICIAL_RELATIONSHIP', 523), ('SUPERFICIAL_RELATIONSHIP', 534)]	6	[('NCBITaxon_9606', 'Homo sapiens', 10, 'human'), ('SO_0000704', 'gene', 20, 'genes'), ('PR_000003775', '1,2-dihydroxy-3-keto-5-methylthiopentene dioxygenase', 136, 'ADH1C'), ('PR_000003790', 'ADP-ribose glycohydrolase ARH3', 144, 'ADH1B'), ('PR_000003790', 'ADP-ribose glycohydrolase ARH3', 152, 'ADH1A'), ('SO_0000441', 'ss_oligo', 238, 'noncoding'), ('SO_0000704', 'gene', 267, 'genes'), ('PR_000003790', 'ADP-ribose glycohydrolase ARH3', 387, 'ADH1B'), ('SO_0001023', 'allele', 395, 'allele'), ('CHEBI_30879', 'alcohol', 549, 'alcohol'), ('CHEBI_16236', 'ethanol', 622, 'ethanol'), ('CHEBI_15343', 'acetaldehyde', 654, 'acetaldehyde')]
S52-PMC4910734	PMC4910734	6/2015	S52-PMC4910734	['one EXPLANATION APPEARS TO be that mutations increasing the Ethanol oxidation cannot be INTERPRETED in isolation from INFORMATION about the corresponding Aldh2 Gene, which MAY or MAY not rapidly Metabolize any excess Acetaldehyde generated by mutant adh Genes.']	[('PROBABLE_UNDERSTANDING', 4), ('ANOMALY_CURIOUS_FINDING', 16), ('FULL_UNKNOWN', 88), ('INCOMPLETE_EVIDENCE', 118), ('INCOMPLETE_EVIDENCE', 172), ('INCOMPLETE_EVIDENCE', 179)]	6	[('CHEBI_16236', 'ethanol', 60, 'ethanol'), ('PR_000003923', 'aldehyde dehydrogenase X, mitochondrial', 154, 'ALDH2'), ('SO_0000704', 'gene', 160, 'gene'), ('GO_0008152', 'metabolic process', 195, 'metabolize'), ('CHEBI_15343', 'acetaldehyde', 217, 'acetaldehyde'), ('SO_0000704', 'gene', 254, 'genes')]
S153-PMC4910734	PMC4910734	6/2015	S153-PMC4910734	['in the alcoholism literature, Acetaldehyde accumulation results, NOT ONLY from an excess of Ethanol ingestion, BUT ALSO from the Genetic errors, which predispose an Individual to alcoholism.']	[('ANOMALY_CURIOUS_FINDING', 65), ('ANOMALY_CURIOUS_FINDING', 111)]	2	[('CHEBI_15343', 'acetaldehyde', 30, 'acetaldehyde'), ('CHEBI_16236', 'ethanol', 92, 'ethanol'), ('SO_0000704', 'gene', 129, 'genetic'), ('NCBITaxon_1', 'root', 165, 'individual')]
S154-PMC4910734	PMC4910734	6/2015	S154-PMC4910734	['SOME of the KNOWN Genetic errors involve the primary Ethanol-Metabolizing Genes: the adh isozymes and Aldh2 .19,128,129in the absence of Ethanol, the adhs and Aldh2 catalyze OTHER substrates, PRIMARILY INVOLVED in Retinol Metabolism14,15and Neurotransmitter Catabolism.16if an Individual has inherited mutations, which lead to an accumulation of Acetaldehyde during Ethanol Ingestion, these same mutations will lead to an accumulation of OTHER types of Aldehydes in the absence of Ethanol.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 12), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 174), ('PROBABLE_UNDERSTANDING', 192), ('SUPERFICIAL_RELATIONSHIP', 202), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 438)]	6	[('SO_0000704', 'gene', 18, 'genetic'), ('CHEBI_16236', 'ethanol', 53, 'ethanol'), ('GO_0006098', 'pentose-phosphate shunt', 53, 'ethanol-metabolizing'), ('SO_0000704', 'gene', 74, 'genes'), ('PR_000003923', 'aldehyde dehydrogenase X, mitochondrial', 102, 'ALDH2'), ('CHEBI_16236', 'ethanol', 137, 'ethanol'), ('PR_000003923', 'aldehyde dehydrogenase X, mitochondrial', 159, 'ALDH2'), ('CHEBI_26536', 'retinoic acid', 214, 'retinol'), ('GO_0031009', 'plastid ADPG pyrophosphorylase complex', 214, 'retinol metabolism14'), ('CHEBI_25512', 'neurotransmitter', 241, 'neurotransmitter'), ('GO_0042135', 'neurotransmitter catabolic process', 241, 'neurotransmitter catabolism'), ('NCBITaxon_1', 'root', 277, 'individual'), ('CHEBI_15343', 'acetaldehyde', 346, 'acetaldehyde'), ('CHEBI_16236', 'ethanol', 366, 'ethanol'), ('GO_0007631', 'feeding behavior', 374, 'ingestion'), ('CHEBI_17478', 'aldehyde', 453, 'aldehydes'), ('CHEBI_16236', 'ethanol', 481, 'ethanol')]
S159-PMC4910734	PMC4910734	6/2015	S159-PMC4910734	['IF some subsets of autistic children have inherited Genes, which predispose them to alcoholism, then in the absence of Ethanol, they are LIKELY to have Metabolic reactions that result in an accumulation of endogenous Aldehydes with similar consequences to that of Acetaldehyde toxicity.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('PROBABLE_UNDERSTANDING', 137)]	2	[('SO_0000704', 'gene', 52, 'genes'), ('CHEBI_16236', 'ethanol', 119, 'ethanol'), ('GO_0008152', 'metabolic process', 152, 'metabolic'), ('CHEBI_17478', 'aldehyde', 217, 'aldehydes'), ('CHEBI_15343', 'acetaldehyde', 264, 'acetaldehyde')]
S61-PMC5901203	PMC5901203	4/2018	S61-PMC5901203	['Pharmacological options include low-dose Aspirin, Acetaminophen, and short use of nsaids.96non-Pharmacological treatment options include patient education with or without physiotherapy,97mechanical supports, tens; exercise, craniosacral therapy, osteomanipulative therapy, multi-modal intervention, and acupuncture.98data are CONFLICTING regarding efficacy of the aforementioned options, and 75% of providers will not recommend any formal treatment.87,88a 2013 cochrane review FOUND moderate-quality EVIDENCE SUPPORTING acupuncture and exercise for Pelvic or Lumbopelvic pain and low-QUALITY EVIDENCE SUPPORTING exercise for Low Back pain.99meanwhile, a 2015 cochrane review by the same authors FOUND low-QUALITY evidence supporting the ROLE of exercise in reducing Low Back pain and moderate-to-low quality EVIDENCE that exercise improves functional disability.100the latter review also FOUND that acupuncture, craniosacral therapy, osteomanipulative therapy, and multmodal intervention MAY BE of benefit to Pregnant women with Pelvic pain.100a systematic review for physical therapy FOUND no strong EVIDENCE IN SUPPORT of therapeutic EFFECTS;101HOWEVER, the same authors FOUND that physical therapy is an effective treatment for Pelvic Girdle pain and adding specific stabilizing exercises provides a POTENTIAL advantage.102acupuncture is also EFFECTIVE when compared to physiotherapy, and both acupuncture and physiotherapy are superior to education only.103pelvic support belts provided no advantage over education and exercise.104likewise, there is no benefit to Pelvic Girdle pain with an education group, home exercise group, or supervised exercise group when participants are provided a non-elastic Sacroiliac Belt.105group education by itself HAS also BEEN FOUND TO BE ineffective.106case STUDIES SUPPORT the use of instrument-assisted soft Tissue mobilization107as well as acupuncture combined with Opioids.108\n\nchronic pain ASSOCIATED with mode of Delivery (Vaginal vs cesarean)\nWHILE SOME STUDIES HAVE SHOWN that the risk of chronic pain after Pregnancy is RARE at 0.3%,109other STUDIES HAVE SHOWN a more common prevalence rate of 10%.110studies HAVE SHOWN that Delivery mode is not related to the risk of experiencing pain at 8 weeks,1113 months,112and 2 years.113ON THE OTHER HAND, mode of Delivery may impact the PREVALENCE AS rates are 0.6%–22% following caesarean Delivery and 1%–10% with Vaginal Delivery.114–123in the loan study investigating Deliveries with an episiotomy, up to 12.8% of patients had chronic pain lasting a minimum of 5 months.124\nlavand’homme has published extensively about chronic pain after Delivery and NOTED five KEY points: 1) incidence of persistent postsurgical pain after Childbirth is lower than similar surgical procedures; 2) pain characteristics are POORLY detailed; 3) after a cesarean Delivery, pain is PRIMARILY low-intensity neuropathic pain; 4) the extent of trauma is not PREDICTIVE of pain severity; and 5) the aforementioned findings SUGGEST that PROTECTIVE Antinociceptive mechanisms occur during the Perinatal Period.115,125,126others have ECHOED the prevalence of neuropathic pain after cesarean Delivery.127\nNOTABLE risk factors for Postpartum chronic pain include a history of previous chronic pain disorder and higher Postoperative pain severity110,111,119,121,128but not Epidural analgesia.129use of general anesthesia, non-private insurance status, emergency cesarean Delivery, and psychological indication for cesarean Delivery are RISK FACTORS NOTED with caesarean Delivery ONLY.109,117,119,130,131in the lone Genetic study, polymorphisms of the atp-Binding Cassette Sub-Family B Member-1 Gene were not associated with the increased risk for development of chronic pain following a cesarean section, but a TREND was FOUND for women with the t Allele of tc3435t polymorphism.132\nthe RELATIONSHIP between Analgesic methods (ie, Intrathecal Clonidine, wound infiltration, transversus Abdominal plane block, intravenous Ketamine, oral Gabapentin, and pregabalin) and development of chronic Pain following an operative Abdominal Delivery in the Postpartum period have BEEN discussed extensively and the following surgical techniques HAVE BEEN IMPLICATED as risk FACTORS: larger surgical incisions with INCREASED RISKS for lateral Nerve entrapment and neuromas, Uterine exteriorization and Parietal Peritoneal closure,121and repeated surgical procedures as a cause for hypersensitization.133two articles compared patients based on surgical technique, pfannenstiel or misgav-ladach,134,135and results favored the misgav-ladach technique.134,135multiple pfannenstiel incisions HAVE BEEN SHOWN to PREDICT chronic pain at 12 months.131postoperative treatment of pain also IMPACTS the Development Of Postpartum chronic Pain as higher doses of Local Anesthetic and the use of Anti-Inflammatory Medicines Postoperatively decreased the incidence of chronic pain at 3 months.130to decrease post-cesarean pain, a double-blind placebo-controlled trial compared Intravenous Magnesium Sulfate in low and high doses with a control group and observed that short-term pain and long-term pain (6 weeks) were SIMILAR between the magnesium arms and a control group of women.136the impact of Postpartum chronic pain on neonatal outcomes or women’s quality of Life is LARGELY UNSTUDIED, but one investigation FOUND a negative IMPACT on sexual and nonsexual activities.110\nour literature search FAILED TO find any discussion on the preferred treatment options for Postpartum chronic pain with EXCEPTION of the neuromas.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 326), ('INCOMPLETE_EVIDENCE', 477), ('INCOMPLETE_EVIDENCE', 500), ('INCOMPLETE_EVIDENCE', 509), ('INCOMPLETE_EVIDENCE', 584), ('INCOMPLETE_EVIDENCE', 592), ('INCOMPLETE_EVIDENCE', 601), ('INCOMPLETE_EVIDENCE', 695), ('INCOMPLETE_EVIDENCE', 704), ('SUPERFICIAL_RELATIONSHIP', 737), ('INCOMPLETE_EVIDENCE', 808), ('INCOMPLETE_EVIDENCE', 888), ('INCOMPLETE_EVIDENCE', 988), ('INCOMPLETE_EVIDENCE', 1085), ('INCOMPLETE_EVIDENCE', 1101), ('INCOMPLETE_EVIDENCE', 1113), ('SUPERFICIAL_RELATIONSHIP', 1136), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1144), ('INCOMPLETE_EVIDENCE', 1173), ('INCOMPLETE_EVIDENCE', 1303), ('SUPERFICIAL_RELATIONSHIP', 1346), ('INCOMPLETE_EVIDENCE', 1752), ('ANOMALY_CURIOUS_FINDING', 1766), ('INCOMPLETE_EVIDENCE', 1766), ('INCOMPLETE_EVIDENCE', 1798), ('INCOMPLETE_EVIDENCE', 1806), ('SUPERFICIAL_RELATIONSHIP', 1935), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1990), ('INCOMPLETE_EVIDENCE', 1996), ('INCOMPLETE_EVIDENCE', 2009), ('INCOMPLETE_EVIDENCE', 2069), ('INCOMPLETE_EVIDENCE', 2091), ('INCOMPLETE_EVIDENCE', 2099), ('INCOMPLETE_EVIDENCE', 2158), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 2274), ('IMPORTANT_CONSIDERATION', 2328), ('PROBABLE_UNDERSTANDING', 2339), ('ANOMALY_CURIOUS_FINDING', 2645), ('IMPORTANT_CONSIDERATION', 2656), ('PROBLEM_COMPLICATION', 2801), ('PROBABLE_UNDERSTANDING', 2856), ('SUPERFICIAL_RELATIONSHIP', 2929), ('INCOMPLETE_EVIDENCE', 2993), ('SUPERFICIAL_RELATIONSHIP', 3006), ('INCOMPLETE_EVIDENCE', 3101), ('ANOMALY_CURIOUS_FINDING', 3171), ('IMPORTANT_CONSIDERATION', 3171), ('SUPERFICIAL_RELATIONSHIP', 3500), ('ANOMALY_CURIOUS_FINDING', 3513), ('INCOMPLETE_EVIDENCE', 3543), ('INCOMPLETE_EVIDENCE', 3775), ('INCOMPLETE_EVIDENCE', 3785), ('SUPERFICIAL_RELATIONSHIP', 3851), ('ANOMALY_CURIOUS_FINDING', 4132), ('INCOMPLETE_EVIDENCE', 4197), ('SUPERFICIAL_RELATIONSHIP', 4207), ('SUPERFICIAL_RELATIONSHIP', 4226), ('IMPORTANT_CONSIDERATION', 4266), ('INCOMPLETE_EVIDENCE', 4638), ('SUPERFICIAL_RELATIONSHIP', 4657), ('SUPERFICIAL_RELATIONSHIP', 4731), ('SUPERFICIAL_RELATIONSHIP', 5154), ('INCOMPLETE_EVIDENCE', 5310), ('INCOMPLETE_EVIDENCE', 5318), ('INCOMPLETE_EVIDENCE', 5351), ('SUPERFICIAL_RELATIONSHIP', 5368), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 5436), ('QUESTION_ANSWERED_BY_THIS_WORK', 5443), ('ANOMALY_CURIOUS_FINDING', 5534)]	69	[('CHEBI_52217', 'pharmaceutical', 0, 'Pharmacological'), ('CHEBI_2904', 'atenolol', 41, 'aspirin'), ('CHEBI_15343', 'acetaldehyde', 50, 'acetaminophen'), ('CHEBI_52217', 'pharmaceutical', 95, 'pharmacological'), ('UBERON_0002108', 'small intestine', 549, 'pelvic'), ('UBERON_0001230', 'glomerular capsule', 559, 'lumbopelvic'), ('UBERON_0001708', 'jaw skeleton', 625, 'low'), ('UBERON_0001137', 'dorsum', 629, 'back'), ('UBERON_0008943', 'headfoot', 766, 'low back'), ('GO_0007565', 'female pregnancy', 1009, 'pregnant'), ('UBERON_0002108', 'small intestine', 1029, 'pelvic'), ('UBERON_0001008', 'renal system', 1231, 'pelvic girdle'), ('UBERON_0001008', 'renal system', 1568, 'pelvic girdle'), ('UBERON_0018154', 'ligament of middle ear', 1707, 'sacroiliac belt'), ('UBERON_0000479', 'tissue', 1850, 'tissue'), ('CHEBI_35998', 'tridecane', 1909, 'opioids'), ('GO_0007567', 'parturition', 1959, 'delivery'), ('UBERON_0001987', 'placenta', 1969, 'vaginal'), ('GO_0007565', 'female pregnancy', 2056, 'pregnancy'), ('GO_0007567', 'parturition', 2174, 'delivery'), ('GO_0007567', 'parturition', 2304, 'delivery'), ('GO_0007567', 'parturition', 2381, 'delivery'), ('GO_0007601', 'visual perception', 2406, 'vaginal'), ('GO_0007567', 'parturition', 2414, 'delivery'), ('GO_0007567', 'parturition', 2462, 'deliveries'), ('GO_0007567', 'parturition', 2632, 'delivery'), ('GO_0007623', 'circadian rhythm', 2719, 'childbirth'), ('GO_0007567', 'parturition', 2838, 'delivery'), ('GO_0019267', 'asparagine biosynthetic process from cysteine', 3017, 'antinociceptive'), ('GO_0036268', 'swimming', 3061, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 3061, 'perinatal period'), ('GO_0007567', 'parturition', 3158, 'delivery'), ('GO_0007565', 'female pregnancy', 3196, 'postpartum'), ('GO_0007565', 'female pregnancy', 3283, 'postoperative'), ('UBERON_2000660', 'epural', 3337, 'epidural'), ('GO_0007567', 'parturition', 3435, 'delivery'), ('GO_0007567', 'parturition', 3487, 'delivery'), ('GO_0007567', 'parturition', 3534, 'delivery'), ('SO_0000704', 'gene', 3579, 'genetic'), ('PR_000009339', 'killer cell immunoglobulin-like receptor 3DL3', 3619, 'binding cassette sub-family B member-1'), ('SO_0000409', 'binding_site', 3619, 'binding cassette'), ('SO_0000704', 'gene', 3658, 'gene'), ('SO_0001023', 'allele', 3812, 'allele'), ('CHEBI_35480', 'analgesic', 3872, 'analgesic'), ('GO_0009057', 'macromolecule catabolic process', 3872, 'analgesic'), ('UBERON_0018332', 'jugal bar', 3895, 'intrathecal'), ('CHEBI_3743', 'clidinium', 3907, 'clonidine'), ('UBERON_0000916', 'abdomen', 3950, 'abdominal'), ('CHEBI_6121', 'ketamine', 3985, 'ketamine'), ('CHEBI_42797', 'gabapentin', 4000, 'gabapentin'), ('GO_0030263', 'apoptotic chromosome condensation', 4055, 'pain'), ('UBERON_0000916', 'abdomen', 4083, 'abdominal'), ('GO_0007567', 'parturition', 4093, 'delivery'), ('GO_0007565', 'female pregnancy', 4109, 'postpartum'), ('UBERON_0001021', 'nerve', 4294, 'nerve'), ('UBERON_0000995', 'uterus', 4325, 'uterine'), ('UBERON_0001375', 'semitendinosus', 4353, 'parietal peritoneal'), ('GO_0046697', 'decidualization', 4743, 'development of'), ('GO_0009058', 'biosynthetic process', 4758, 'postpartum ... pain'), ('CHEBI_36333', 'local anaesthetic', 4801, 'local anesthetic'), ('CHEBI_73154', 'victorin C', 4833, 'anti-inflammatory medicines'), ('GO_0050817', 'coagulation', 4861, 'postoperatively'), ('UBERON_0034986', 'sacral nerve plexus', 5013, 'intravenous'), ('CHEBI_32599', 'magnesium sulfate', 5025, 'magnesium sulfate'), ('GO_0007565', 'female pregnancy', 5235, 'postpartum'), ('UBERON_0000104', 'life cycle', 5302, 'life'), ('GO_0007565', 'female pregnancy', 5505, 'postpartum')]
S9289-PMC4896250	PMC4896250	4/2016	S9289-PMC4896250	['a650 a case of occupational contact dermatitis caused by N-Acetylcysteine\n\nji hye kim, moon gyeong yoon, young min ye, yoo seob shin, ga young ban, hae-sim park, hye min jung\n\najou university school of medicine, south korea\n\ncorrespondence: ji hye kim – ajou university school of medicine, south korea\nN-Acetylcysteine(Nac) is widely used Drug as a mucolytic in chronic Respiratory diseases, an Antidote in Acetaminophen overdose and a PROTECTIVE agent for Renal function in contrast-induced nephropathy.']	[('SUPERFICIAL_RELATIONSHIP', 436)]	1	[('CHEBI_70979', 'N-isobutyrylglycine', 57, 'N-Acetylcysteine'), ('CHEBI_70981', '6-formylpterin', 302, 'N-acetylcysteine'), ('CHEBI_7421', 'NAC', 319, 'NAC'), ('CHEBI_23888', 'drug', 339, 'drug'), ('UBERON_0001004', 'respiratory system', 370, 'respiratory'), ('CHEBI_50247', 'antidote', 395, 'antidote'), ('CHEBI_15343', 'acetaldehyde', 407, 'acetaminophen'), ('UBERON_0002113', 'kidney', 457, 'renal')]
S73-PMC4910734	PMC4910734	6/2015	S73-PMC4910734	['in one b1 mechanism DEMONSTRATED in vitro, the Electrophilic Acetaldehyde attacks the c2 adjacent to the Sulfur in the Thiophene Ring of b1, thereby lowering the bioavailability of b1.40one mechanism for the decrease in Hepatic Glutathione levels involves the binding of the Reactive Acetaldehyde, not to Glutathione directly, but to the Glutathione intermediate cysteinylglycine.41similarly, Acetaldehyde also reacts directly with selective Amino Acids and Sulfur-containing antioxidants, such as N -Acetylcysteine (Nac) and Taurine.42ethanol ingestion is also known to induce Folate deficiencies, with one mechanism DEMONSTRATING the Acetaldehyde-induced cleavage of Folate by Xanthine oxidase.43ALTHOUGH there are no reports of b6-Acetaldehyde adducts, the activated form of b6, Pyridoxal-5-Phosphate (p5p), is a type of Aldehyde, which is known to form condensation products with other Aldehydes, thereby decreasing the bioavailability of b6.']	[('INCOMPLETE_EVIDENCE', 20), ('INCOMPLETE_EVIDENCE', 618), ('ANOMALY_CURIOUS_FINDING', 696)]	3	"[('CHEBI_39231', 'emamectin B1a', 47, 'electrophilic'), ('CHEBI_15343', 'acetaldehyde', 61, 'acetaldehyde'), ('CHEBI_36933', 'oxygen-19 atom', 105, 'sulfur'), ('CHEBI_52885', 'Po-Pro-1(2+)', 119, 'thiophene ring'), ('UBERON_0002107', 'liver', 220, 'hepatic'), ('CHEBI_16856', 'glutathione', 228, 'glutathione'), ('CHEBI_33893', 'reagent', 275, 'reactive'), ('CHEBI_15343', 'acetaldehyde', 284, 'acetaldehyde'), ('CHEBI_16856', 'glutathione', 305, 'glutathione'), ('CHEBI_16856', 'glutathione', 338, 'glutathione'), ('CHEBI_15343', 'acetaldehyde', 393, 'acetaldehyde'), ('CHEBI_33867', 'idonates', 442, 'amino acids'), ('CHEBI_36933', 'oxygen-19 atom', 458, 'sulfur'), ('CHEBI_70981', '6-formylpterin', 498, 'N -acetylcysteine'), ('CHEBI_7421', 'NAC', 517, 'NAC'), ('CHEBI_15891', 'taurine', 526, 'taurine'), ('CHEBI_30863', '5-azaorotic acid', 578, 'folate'), ('CHEBI_15343', 'acetaldehyde', 636, 'acetaldehyde'), ('CHEBI_30863', '5-azaorotic acid', 669, 'folate'), ('CHEBI_17957', '5-(2-hydroxyethyl)-4-methylthiazole', 679, 'xanthine'), ('CHEBI_15343', 'acetaldehyde', 734, 'acetaldehyde'), ('CHEBI_18335', ""pyridoxamine 5'-phosphate"", 782, 'pyridoxal-5-phosphate'), ('CHEBI_17478', 'aldehyde', 824, 'aldehyde'), ('CHEBI_17478', 'aldehyde', 890, 'aldehydes')]"
S124-PMC5901203	PMC5901203	4/2018	S124-PMC5901203	['following a Vaginal Delivery, patients will BENEFIT from scheduled Acetaminophen and Ibuprofen.']	[('IMPORTANT_CONSIDERATION', 44)]	1	[('GO_0007601', 'visual perception', 12, 'vaginal'), ('UBERON_0001987', 'placenta', 12, 'vaginal'), ('GO_0007567', 'parturition', 20, 'delivery'), ('CHEBI_15343', 'acetaldehyde', 67, 'acetaminophen'), ('CHEBI_76162', 'indoprofen', 85, 'ibuprofen')]
S38-PMC5901203	PMC5901203	4/2018	S38-PMC5901203	['jones et al discussed the methodological LIMITATIONS of CURRENT RESEARCH and THE NEED for FUTURE RESEARCH on the use of Opioids in Pregnancy for chronic pain disorders.9\nAcetaminophen is the most common nonprescription Medication RECOMMENDED during Pregnancy to treat pain and HAS BEEN RECENTLY ASSOCIATED with INCREASED RISK for Respiratory, Testicular, attention-deficit/hyperactive-like behavioral, and autism spectrum disorders.24–30THESE results have QUESTIONED the Reproductive SAFETY profile of Acetaminophen; HOWEVER, it REMAINS one of the most commonly used Medications during Pregnancy, specifically for pain indications.']	[('INCOMPLETE_EVIDENCE', 41), ('INCOMPLETE_EVIDENCE', 56), ('INCOMPLETE_EVIDENCE', 77), ('FUTURE_WORK', 81), ('FUTURE_WORK', 90), ('FUTURE_WORK', 230), ('INCOMPLETE_EVIDENCE', 277), ('SUPERFICIAL_RELATIONSHIP', 295), ('IMPORTANT_CONSIDERATION', 311), ('INCOMPLETE_EVIDENCE', 435), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 456), ('INCOMPLETE_EVIDENCE', 456), ('IMPORTANT_CONSIDERATION', 484), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 517), ('INCOMPLETE_EVIDENCE', 529)]	15	[('CHEBI_35998', 'tridecane', 120, 'opioids'), ('GO_0007565', 'female pregnancy', 131, 'pregnancy'), ('CHEBI_2404', 'acetosyringone', 170, 'Acetaminophen'), ('CHEBI_60211', 'compound Z', 219, 'medication'), ('GO_0007565', 'female pregnancy', 249, 'pregnancy'), ('UBERON_0001004', 'respiratory system', 330, 'respiratory'), ('UBERON_0000473', 'testis', 343, 'testicular'), ('GO_0000003', 'reproduction', 471, 'reproductive'), ('CHEBI_15343', 'acetaldehyde', 502, 'acetaminophen'), ('CHEBI_25441', 'mycothiols', 567, 'medications'), ('GO_0007565', 'female pregnancy', 586, 'pregnancy')]
S71-PMC4910734	PMC4910734	6/2015	S71-PMC4910734	['prolonged Ethanol consumption is KNOWN to cause oxidative stress35and induce DEFICIENCIES in a number of key Nutrients, including but not limited to Retinol, Glutathione, Zn2+, b1, b6, and Folate.36ALTHOUGH the Nutrient-deficient status of an alcoholic is OFTEN ATTRIBUTED to a nutrient-poor diet or to Ethanol-induced malabsorption, the reality is much more COMPLEX.37the mechanism for SOME Micronutrient deficiencies includes direct reactions with the electrophilic Acetaldehyde generated during Ethanol Metabolism.']	[('INCOMPLETE_EVIDENCE', 33), ('IMPORTANT_CONSIDERATION', 77), ('ANOMALY_CURIOUS_FINDING', 196), ('ANOMALY_CURIOUS_FINDING', 196), ('PROBABLE_UNDERSTANDING', 256), ('SUPERFICIAL_RELATIONSHIP', 262), ('DIFFICULT_TASK', 359), ('INCOMPLETE_EVIDENCE', 387)]	8	[('CHEBI_16236', 'ethanol', 10, 'ethanol'), ('CHEBI_33284', 'nutrient', 109, 'nutrients'), ('CHEBI_26536', 'retinoic acid', 149, 'retinol'), ('CHEBI_16856', 'glutathione', 158, 'glutathione'), ('CHEBI_29105', 'zinc(2+)', 171, 'Zn2+,'), ('CHEBI_30863', '5-azaorotic acid', 189, 'folate'), ('CHEBI_33284', 'nutrient', 211, 'nutrient'), ('CHEBI_16236', 'ethanol', 303, 'ethanol'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 392, 'micronutrient'), ('CHEBI_15343', 'acetaldehyde', 468, 'acetaldehyde'), ('CHEBI_16236', 'ethanol', 498, 'ethanol'), ('GO_0006067', 'ethanol metabolic process', 498, 'ethanol metabolism')]
S140-PMC4910734	PMC4910734	6/2015	S140-PMC4910734	['Acetaldehyde also forms covalent adducts with accessible reactive Amino Acids on proteins, not ONLY inactivating the proteins, BUT releasing Zn2+.']	[('ANOMALY_CURIOUS_FINDING', 95), ('ANOMALY_CURIOUS_FINDING', 127)]	2	[('CHEBI_15343', 'acetaldehyde', 0, 'Acetaldehyde'), ('CHEBI_33867', 'idonates', 66, 'amino acids'), ('CHEBI_29105', 'zinc(2+)', 141, 'Zn2+.')]
